Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole – A probe drug of CYP2C19 metabolism - 16/01/22
, Christoph Weiser aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
Targeted temperature management (TTM) is part of standard post-resuscitation care. TTM may downregulate cytochrome enzyme activity and thus impact drug metabolism. This study compared the pharmacokinetics (PK) of pantoprazole, a probe drug of CYP2C19-dependent metabolism, at different stages of TTM following cardiac arrest.
Methods |
This prospective controlled study was performed at the Medical University of Vienna and enrolled 16 patients following cardiac arrest. The patients completed up to three study periods (each lasting 24 h) in which plasma concentrations of pantoprazole were quantified: (P1) hypothermia (33 °C) after admission, (P2) normothermia after rewarming (36 °C, intensive care), and (P3) normothermia during recovery (normal ward, control group). PK was analysed using non-compartmental analysis and nonlinear mixed-effects modelling.
Results |
16 patients completed periods P1 and P2; ten completed P3. The median half-life of pantoprazole was 2.4 h (quartiles: 1.8–4.8 h) in P1, 2.8 h (2.1–6.8 h, p = 0.046 vs. P1, p = 0.005 vs. P3) in P2 and 1.2 h (0.9 – 2.3 h, p = 0.007 vs. P1) in P3. A two-compartment model described the PK data best. Typical values for clearance were estimated separately for each study period, indicating 40% and 29% reductions during P1 and P2, respectively, compared to P3. The central volume of distribution was estimated separately for P2, indicating a 64% increase compared to P1 and P3.
Conclusion |
CYP2C19-dependent drug metabolism is downregulated during TTM following cardiac arrest. These results may influence drug choice and dosing of similarly metabolized drugs and may be helpful for designing studies in similar clinical situations.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | We included cardiac arrest patients during therapeutic hypothermia at 33 °C, after rewarming (ICU) and after recovery. |
• | The pharmacokinetics of pantoprazole, a CYP2C19 probe drug, during these treatment stages were compared. |
• | During hypothermia and after rewarming (ICU), the metabolism of pantoprazole was reduced compared with normal ward stay. |
• | The initial hypothermia and the systemic inflammatory response after cardiac arrest may impair CYP2C19 activity. |
Keywords : Targeted temperature management, Cardiac arrest, CYP-metabolism, Pharmacokinetics, Intensive care
Plan
Vol 146
Article 112573- février 2022 Retour au numéro
Article précédent
- Multi-activity tetracoordinated pallado-oxadiazole thiones as anti-inflammatory, anti-Alzheimer, and anti-microbial agents: Structure, stability and bioactivity comparison with pallado-hydrazides
- Aisha Abid, Mehreen Lateef, Naushaba Rafiq, Sana Eijaz, Saima Tauseef
- Oral acetaminophen-induced spinal 5-hydroxytriyptamine release produces analgesic effects in the rat formalin test
- Shingo Nakamura, Takahiro Nonaka, Shuji Komatsu, Toshihiko Yamada, Tatsuo Yamamoto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?